Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 29,083 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dose level 1 Clear all
Not yet recruiting Phase 1 Interventional

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

NCT07650357
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Interventions
CLSP-5282
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.

NCT01762475
View directory record Official record
Conditions
Traumatic Brain Injury, Post-concussive Syndrome
Interventions
Sildenafil
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Nov 9, 2026, 5:34 PM EST
Withdrawn Phase 2 Interventional

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

NCT05212701
View directory record Official record
Conditions
Fatigue, Locally Advanced or Metastatic Breast Cancer
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cary, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

NCT04968912
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Placebo, Nipocalimab, Standard of Care Treatment
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
92
States / cities
Mobile, Alabama • Tucson, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT03750565
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1Phase 2 Interventional

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

NCT00052065
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
TLK286
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Nov 9, 2026, 5:34 PM EST
Terminated Phase 2 Interventional Results available

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

NCT01779167
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Thalidomide, Lenalidomide, Rituximab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Nov 9, 2026, 5:34 PM EST
Recruiting Phase 1Phase 2 Interventional

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

NCT04977453
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Squamous Cell Non Small Cell Lung Cancer
Interventions
GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
New York, New York • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks

NCT00604695
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Tenecteplase, Sterile Saline
Drug
Lead sponsor
C. Michael Gibson, MS, MD
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Gainesville, Florida • Atlanta, Georgia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

NCT02692677
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42756493
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1 Interventional

Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia

NCT07802977
View directory record Official record
Conditions
Xerostomia, Head and Neck Squamous Cell Carcinoma
Interventions
Dexamethasone 4mg/mL, Dexamethasone 10mg/mL
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

NCT05178901
View directory record Official record
Conditions
Nipah Virus Infection
Interventions
PHV02, Placebo
Biological · Other
Lead sponsor
Public Health Vaccines LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Nov 9, 2026, 5:34 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

NCT03041701
View directory record Official record
Conditions
Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
Interventions
Dasatinib, Ganitumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

NCT01725230
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib, Rosuvastatin, Simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Nov 9, 2026, 5:34 PM EST
Terminated Phase 2 Interventional Results available

Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain

NCT03407430
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

NCT06363630
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Itraconazole, Rifampin, Golcadomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Nov 9, 2026, 5:34 PM EST
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Nov 9, 2026, 5:34 PM EST
Terminated Phase 1Phase 2 Interventional Results available

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

NCT05091528
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
Interventions
SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1Phase 2 Interventional Results available

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

NCT00633594
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Rituximab, Bortezomib, Lenalidomide
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
Terre Haute, Indiana • Chesterfield, Missouri • Morristown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Nov 9, 2026, 5:34 PM EST
Recruiting Phase 1Phase 2 Interventional

A Study of DS-3939a in Participants With Solid Tumors

NCT07739966
View directory record Official record
Conditions
Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions
DS-3939a, Pembrolizumab, Carboplatin, Pemetrexed, DS-1103a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
7
States / cities
Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

NCT00934856
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Pertuzumab, Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Nov 9, 2026, 5:34 PM EST
Completed Phase 2 Interventional Results available

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia

NCT01656031
View directory record Official record
Conditions
Leukemia
Interventions
clofarabine, cytarabine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 9, 2026, 5:34 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

NCT02083302
View directory record Official record
Conditions
Assaultive Behavior, Violence, Sexual Assault and Rape, Helping Behavior
Interventions
SCREAM Theater Dose 1, SCREAM Theater Doses 2 & SCREAM Theater Dose 3, SCREAM Theater Dose 4
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 21 Years
Enrollment
4,385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Nov 9, 2026, 5:34 PM EST